Healium Medical is pioneering advancements in the field of ablation therapy through its innovative Dual-Mode Ultrasound Technology (DMUT). This technology enables non-contact, continuous ablation therapy while providing real-time tissue monitoring. By utilizing miniature transcatheter ultrasound technology, DMUT delivers precise ultrasonic energy, facilitating safe and rapid lesion placement. This approach significantly simplifies the ablation process, addressing common challenges faced in traditional methods, such as the need for direct tissue contact and the difficulties associated with lesion monitoring.

The company’s focus on developing a no-contact ablation system represents a significant leap forward in treating conditions like atrial fibrillation (AF), which affects millions globally. Healium Medical's solution not only allows for automatic power titration based on tissue thickness but also enhances the safety and efficacy of the procedure by enabling real-time monitoring of lesions. This innovative approach aims to reduce the need for repeat procedures and improve patient outcomes, positioning Healium Medical as a key player in the rapidly growing ablation market, which is projected to reach substantial financial milestones in the coming years.

Israel

Healium Medical is focused on advancing atrial fibrillation treatment with an innovative no-contact guided ablation technology allowing simultenuous tissue ablation and lesion monitoring.   
The company operates out of Alon Medtech Ventures (http://www.alon-medtech.com) in Yokneam, Israel, and have demonstrated its proof-of-concept in an animal model. 
EP Physicians interested to collaborate, contibute to product defintnion and experience the technology first-hand are welcome to contact us.

Healium Medical

Company Details